Oleg Gluz
Breast Centre, Evang. Bethesda-Hospital Moenchengladbach Germany · Breast Centre, Evang. Bethesda-Hospital, Moenchengladbach · Westdeutsche Studiengruppe GmbH
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Oleg Gluz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:10 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07242352 · Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCWomen's Cancer Study Group GmbH · recruiting · Breast Cancer, HR+/HER2- Breast Cancer · principal investigator
- Ph3NCT07178730 · NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerWomen's Cancer Study Group GmbH · not yet recruiting · Breast Cancer, Triple-negative Breast Cancer · principal investigator
- Ph3NCT06081244 · NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)Women's Cancer Study Group GmbH · recruiting · Triple Negative Breast Cancer · principal investigator
- N/ANCT05792150 · PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFSWomen's Cancer Study Group GmbH · recruiting · Female Breast Cancer · principal investigator
- Ph2NCT05704829 · NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerWomen's Cancer Study Group GmbH · recruiting · HER2-positive Early Breast Cancer · principal investigator
- Ph3NCT04565054 · Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBCWomen's Cancer Study Group GmbH · active not recruiting · Breast Cancer Female · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:10 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- 216 citationsRCR 6.6
- 135 citationsRCR 3.3
- 113 citationsRCR 3.0
- 103 citationsRCR 3.4
- Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.J Natl Cancer Inst · 2018100 citationsRCR 3.1
- 97 citationsRCR 2.3
- 80 citationsRCR 1.6
- 79 citationsRCR 4.2
- Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy.Clin Cancer Res · 200756 citationsRCR 1.2
- 43 citationsRCR 1.1